MCID: MCP006
MIFTS: 51

Mucoepidermoid Carcinoma

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Mucoepidermoid Carcinoma

MalaCards integrated aliases for Mucoepidermoid Carcinoma:

Name: Mucoepidermoid Carcinoma 12 53 15 73
Carcinoma, Mucoepidermoid 44
Carcinoma Mucoepidermoid 55
Mec 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4531
MeSH 44 D018277
NCIt 50 C3772
SNOMED-CT 68 4079000
UMLS 73 C0206694

Summaries for Mucoepidermoid Carcinoma

NIH Rare Diseases : 53 Mucoepidermoid carcinoma is a type of cancer of the salivary glands.  Salivary gland cancer is diagnosed in 2-3 individuals per 100,000 people each year, and 30-35% of these are mucoepidermoid carcinomas.   Mucoepidermoid carcinoma develops when a cell randomly acquires changes (mutations) in genes that regulate how the cell divides such that it begins to grow quickly, forming a cluster of cells (a mass or lump).  The earliest signs of a mucoepidermoid carcinoma may include a lump in the face, neck, or mouth; numbness, weakness, or pain in part of the face; or difficulty swallowing.  Treatment often begins with surgery to remove the entire tumor.  In some cases, radiation therapy and/or chemotherapy may be used after surgery to ensure that no cancer cells remain in the body.

MalaCards based summary : Mucoepidermoid Carcinoma, also known as carcinoma, mucoepidermoid, is related to lacrimal gland mucoepidermoid carcinoma and cutaneous mucoepidermoid carcinoma. An important gene associated with Mucoepidermoid Carcinoma is LINC00473 (Long Intergenic Non-Protein Coding RNA 473
In this study, we investigated the role of LINC00473 in mediating CRTC1-MAML2 oncogenic activity in human MEC. We found that LINC00473 transcription was significantly induced in human CRTC1-MAML2-positive MEC cell lines and primary MEC tumors, and was tightly correlated with the CRTC1-MAML2 RNA level. LINC00473 induction was dependent on the ability of CRTC1-MAML2 to activate CREB-mediated transcription. Depletion of LINC00473 significantly reduced the proliferation and survival of human MEC cells in vitro and blocked the in vivo tumor growth in a human MEC xenograft model. RNA in situ hybridization analysis demonstrated a predominantly nuclear localization pattern for LINC00473 in human MEC cells. Furthermore, gene expression profiling revealed that LINC00473 depletion resulted in differential expression of genes important in cancer cell growth and survival. LINC00473 likely regulates gene expression in part through its ability to bind to a cAMP signaling pathway component NONO, enhancing the ability of CRTC1-MAML2 to activate CREB-mediated transcription.
Dysfunction Pattern: Expression), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and O-linked glycosylation. The drugs Emend and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, thyroid and lung, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Disease Ontology : 12 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells.

Wikipedia : 76 Mucoepidermoid carcinoma is the most common type of minor salivary gland malignancy in adults.... more...

Related Diseases for Mucoepidermoid Carcinoma

Diseases related to Mucoepidermoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 lacrimal gland mucoepidermoid carcinoma 34.9 CRTC1 MAML2
2 cutaneous mucoepidermoid carcinoma 34.4 CRTC1 KRT7 MAML2
3 breast mucoepidermoid carcinoma 33.9 ERBB2 MUC1 MUC5AC
4 mucoepidermoid thyroid carcinoma 32.8 CALCA TG
5 bile duct mucoepidermoid carcinoma 32.4 KRT7 MUC1 MUC2 MUC4 MUC5AC
6 warthin tumor 31.5 CRTC1 CRTC3 MAML2
7 pleomorphic adenoma 31.1 ERBB2 KRT14 MUC1 TP63
8 adenocarcinoma 30.7 EGFR ERBB2 MUC1 MUC4
9 hidradenoma 30.6 KRT7 MAML2 MUC1
10 oral cancer 30.5 EGFR KRT13 PCNA
11 adenosquamous carcinoma 30.3 EGFR KRT7 MUC1 MUC4 TP63
12 squamous cell carcinoma 29.9 EGFR ERBB2 MKI67 MUC1 TP63
13 mucinous adenocarcinoma 29.9 EGFR KRT7 MUC1 MUC2
14 basaloid squamous cell carcinoma 29.9 EGFR KRT13 KRT14 KRT7
15 papillary carcinoma 29.9 CALCA ERBB2 KRT7 MUC1 TG
16 renal cell carcinoma, nonpapillary 29.3 EGFR KRT7 LINC00473 MUC1
17 papilloma 29.3 KRT13 KRT14 KRT7 PCNA TP63
18 adenoid cystic carcinoma 29.0 ERBB2 KRT14 KRT7 MKI67 MUC1 PCNA
19 cystadenoma 29.0 CHGA KRT7 MUC1 MUC2 MUC4
20 gastric adenocarcinoma 28.3 CHGA EGFR ERBB2 KRT7 MUC2 MUC4
21 lung cancer 26.6 AREG CHGA EGFR ERBB2 KRT7 LINC00473
22 sclerosing mucoepidermoid carcinoma with eosinophilia 12.4
23 thymus mucoepidermoid carcinoma 12.2
24 lung mucoepidermoid carcinoma 12.2
25 laryngeal mucoepidermoid carcinoma 12.2
26 bronchus mucoepidermoid carcinoma 11.9
27 trachea mucoepidermoid carcinoma 11.9
28 mucoepidermoid esophageal carcinoma 11.4
29 paranasal sinus cancer 11.2
30 breast intraductal proliferative lesion 11.0 EGFR ERBB2
31 clear cell hidradenoma 10.9 CRTC1 MAML2
32 cervical adenosquamous carcinoma 10.9 CRTC1 EGFR MAML2
33 breast cystic hypersecretory carcinoma 10.9 ERBB2 TG
34 malignant peritoneal mesothelioma 10.9 EGFR MUC1
35 intracystic papillary adenoma 10.9 EGFR ERBB2
36 progesterone-receptor negative breast cancer 10.9 EGFR ERBB2
37 solid adenocarcinoma with mucin production 10.8 KRT7 MUC1
38 suppurative thyroiditis 10.8 CALCA TG
39 cystic basal cell carcinoma 10.8 KRT7 TP63
40 breast scirrhous carcinoma 10.8 EGFR ERBB2 MUC1
41 thyroid sarcoma 10.8 CALCA TG
42 brain ependymoma 10.7 EGFR MKI67
43 breast squamous cell carcinoma 10.7 EGFR ERBB2 KRT14
44 pancreatic intraductal papillary-mucinous neoplasm 10.7 MUC1 MUC2
45 endosalpingiosis 10.7 KRT7 MUC1
46 lipid-rich carcinoma 10.7 EGFR ERBB2 KRT14
47 ovarian germ cell teratoma 10.7 KRT7 TG
48 pre-malignant neoplasm 10.7 EGFR ERBB2 KRT14
49 epispadias 10.7 CALCA ERBB2 TP63
50 in situ carcinoma 10.7 EGFR ERBB2 KRT14

Graphical network of the top 20 diseases related to Mucoepidermoid Carcinoma:



Diseases related to Mucoepidermoid Carcinoma

Symptoms & Phenotypes for Mucoepidermoid Carcinoma

MGI Mouse Phenotypes related to Mucoepidermoid Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 MUC5AC TP63 AREG EGFR ERBB2 KRT14
2 endocrine/exocrine gland MP:0005379 9.65 AREG CHGA CRTC1 EGFR ERBB2 KRT14
3 homeostasis/metabolism MP:0005376 9.4 AREG CHGA CRTC1 CRTC3 EGFR ERBB2

Drugs & Therapeutics for Mucoepidermoid Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003

Drugs for Mucoepidermoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
2
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
4
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
5
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
6
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
7
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
10 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
11 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
12 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
13 Antimitotic Agents Phase 3,Phase 1,Phase 2
14
Megestrol Phase 3 3562-63-8 19090 3080587
15
Histamine Phosphate Phase 3 51-74-1 65513
16 Analgesics Phase 3
17 Central Nervous System Depressants Phase 3
18 Adjuvants, Anesthesia Phase 3
19 Central Nervous System Stimulants Phase 3,Not Applicable
20 Cholinergic Agents Phase 3,Not Applicable
21 Narcotics Phase 3
22 Steroid Synthesis Inhibitors Phase 2, Phase 3
23 Contraceptive Agents Phase 3
24 Contraceptives, Oral Phase 3
25 Neurotransmitter Agents Phase 3,Not Applicable
26 Histamine Antagonists Phase 3
27 Analgesics, Opioid Phase 3
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
29 Anesthetics Phase 3
30 Hormone Antagonists Phase 2, Phase 3
31 Anesthetics, General Phase 3
32 Anesthetics, Intravenous Phase 3
33 Hormones Phase 2, Phase 3,Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
35 Peripheral Nervous System Agents Phase 3,Not Applicable
36 Antidepressive Agents Phase 3
37 Antidepressive Agents, Tricyclic Phase 3
38 Antifungal Agents Phase 2, Phase 3,Phase 1
39 Psychotropic Drugs Phase 3
40 Autonomic Agents Phase 3,Not Applicable
41 Appetite Stimulants Phase 3
42 Antineoplastic Agents, Hormonal Phase 3
43 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
44
Cisplatin Approved Phase 1, Phase 2,Phase 2 15663-27-1 84093 441203 2767
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Indinavir Approved Phase 2 150378-17-9 5362440
47
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
48
Amifostine Approved, Investigational Phase 1, Phase 2,Phase 2 20537-88-6 2141
49
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
50
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
4 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
5 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
6 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
7 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
8 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
9 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
12 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
13 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
14 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
15 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
16 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
17 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
18 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
19 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
20 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
21 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
22 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
23 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
24 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
25 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
26 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
27 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery Recruiting NCT01220583 Phase 2 cisplatin
28 Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Active, not recruiting NCT01586767 Phase 2
29 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
30 Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Terminated NCT00126607 Phase 2
31 Title XELOX FOR SALIVARY GLAND CANCERS Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
32 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
33 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
34 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
35 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
36 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
37 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
38 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
39 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
40 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
41 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
42 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
43 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
44 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
45 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
46 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
47 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
48 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
49 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
50 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib

Search NIH Clinical Center for Mucoepidermoid Carcinoma

Cochrane evidence based reviews: carcinoma, mucoepidermoid

Genetic Tests for Mucoepidermoid Carcinoma

Anatomical Context for Mucoepidermoid Carcinoma

MalaCards organs/tissues related to Mucoepidermoid Carcinoma:

41
Salivary Gland, Thyroid, Lung, Brain, Liver, Skin, Trachea

Publications for Mucoepidermoid Carcinoma

Articles related to Mucoepidermoid Carcinoma:

(show top 50) (show all 723)
# Title Authors Year
1
Mucoepidermoid Carcinoma: A 23-Year Experience with Emphasis on Low-Grade Tumors with Close/Positive Margins. ( 29313462 )
2018
2
Mucoepidermoid Carcinoma Mimicking a Lesion of Endodontic Origin. ( 29935872 )
2018
3
Clinicopathological characteristics and molecular analysis of primary pulmonary mucoepidermoid carcinoma: Case report and literature review. ( 29388384 )
2018
4
Mucoepidermoid Carcinoma of Arising from a Bronchogenic Cyst of the Diaphragm. ( 29367500 )
2018
5
CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells. ( 29353885 )
2018
6
Low grade parotid mucoepidermoid carcinoma with tumour associated lymphoid proliferation ("Warthin-like") and CRTC1-MAML2 fusion transcript: Definitive diagnosis with molecular investigation only. ( 29571603 )
2018
7
Mucoepidermoid carcinoma of the parotid gland: A National Cancer Database study. ( 29559174 )
2018
8
An Extracranial Metastasis of Glioblastoma Mimicking Mucoepidermoid Carcinoma. ( 29852299 )
2018
9
Parotid Mucoepidermoid Carcinoma Mimicking a Large Mucocele. ( 29461375 )
2018
10
Apoptosis induced by methanol extract of PotentillaA discolor in human mucoepidermoid carcinoma cells through STAT3/PUMA signaling axis. ( 29363716 )
2018
11
Pulmonary mucoepidermoid carcinoma: diagnosis and treatment. ( 29338644 )
2018
12
Central mucoepidermoid carcinoma arising from glandular odontogenic cyst confirmed by analysis of MAML2 rearrangement: A case report. ( 29131467 )
2018
13
Central mucoepidermoid carcinoma: An up-to-date analysis of 147 cases and review of prognostic factors. ( 29198377 )
2018
14
You cannot miss it: Pancreatic mucoepidermoid carcinoma: A case report and literature review. ( 29538223 )
2018
15
Surgery combined with radio-chemotherapy for esophageal mucoepidermoid carcinoma: A case report. ( 29901650 )
2018
16
Sclerosing mucoepidermoid carcinoma with eosinophilia: Cytologic characterization of a rare distinct entity in the thyroid. ( 29479842 )
2018
17
Unique application of awake tracheoscopy and endobronchial ultrasound in the management of tracheal mucoepidermoid carcinoma. ( 29575399 )
2018
18
Mucoepidermoid carcinoma of the trachea. ( 29675367 )
2018
19
Mucoepidermoid carcinoma mimicking a mucocele (ranula) in the floor of the mouth. ( 29231036 )
2018
20
Has the management of pediatric mucoepidermoid carcinoma of the parotid gland changed? ( 29658113 )
2018
21
Sclerosing mucoepidermoid carcinoma with eosinophilia of thyroid gland: Not so indolent a neoplasm? ( 29676367 )
2018
22
Expression of vimentin and CD44 in mucoepidermoid carcinoma: A role in tumor growth. ( 29900918 )
2018
23
A Comparative Study of Primary Adenoid Cystic and Mucoepidermoid Carcinoma of Lung. ( 29868475 )
2018
24
Mucoepidermoid Carcinoma (MEC) of Parotid Gland with Massive Cutaneous Involvement: Bilateral Pedicle Advancement Flap (U - Plasty) As Adequate Surgical Approach. ( 29484010 )
2018
25
Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia distinct from the salivary type. ( 29415898 )
2018
26
Low grade mucoepidermoid carcinoma of a minor salivary gland of the tongue in a paediatric patient. ( 29106823 )
2017
27
Warthin Tumor-Like Mucoepidermoid Carcinoma. ( 28793830 )
2017
28
Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. ( 28178760 )
2017
29
Perineural Spread of Mucoepidermoid Carcinoma of Parotid Gland Involving V, VI, and VII Cranial Nerves Demonstrated on Positron Emission Tomography/Computed Tomography. ( 28680219 )
2017
30
Cytological features of the Warthin-like variant of salivary mucoepidermoid carcinoma. ( 28755513 )
2017
31
Fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography findings in a pediatric mucoepidermoid carcinoma and differential diagnosis. ( 28697196 )
2017
32
Nasal cavity tumefactive fibroinflammatory lesion mimicking recurrent mucoepidermoid carcinoma. ( 28846782 )
2017
33
Prognostic factors and occult nodal disease in mucoepidermoid carcinoma of the oral cavity and oropharynx: An analysis of the National Cancer Database. ( 28797455 )
2017
34
Case Report: Recurrent Mucoepidermoid Carcinoma of the Tongue in Adult Female Patient With Lung Cancer. ( 28757800 )
2017
35
18F-FDG PET/CT Imaging of Tracheal Mucoepidermoid Carcinoma. ( 28872555 )
2017
36
Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. ( 28438292 )
2017
37
Dermoscopic features of mucoepidermoid carcinoma of the lip. ( 28593658 )
2017
38
Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature. ( 28343305 )
2017
39
Immunohistochemical expression profiles of mucin antigens in salivary gland mucoepidermoid carcinoma: MUC4- and MUC6-negative expression predicts a shortened survival in the early postoperative phase. ( 28649694 )
2017
40
Sclerosing Mucoepidermoid Carcinoma of the Submandibular Gland Presenting as Chronic Sialadenitis: A Case Report and Review of Literature. ( 28516348 )
2017
41
Low-Grade Mucoepidermoid Carcinoma of the Lacrimal Gland in a Teenaged Patient. ( 29318070 )
2017
42
Bulbar conjunctival metastasis from mucoepidermoid carcinoma of parotid-a case report and review of literature. ( 28061862 )
2017
43
Intraosseous mucoepidermoid carcinoma: Outcome review. ( 28833169 )
2017
44
Mucoepidermoid Carcinoma of Salivary Gland: Limitations and Pitfalls on FNA. ( 28658793 )
2017
45
A Rare Cause of Duodenal Obstruction: Metastatic Parotid Mucoepidermoid Carcinoma. ( 28351791 )
2017
46
Mucoepidermoid Carcinoma in the Skull of an Orange-winged Amazon Parrot (Amazona amazonica). ( 28891704 )
2017
47
Penile warty mucoepidermoid carcinoma with features of stratified mucin-producing intra-epithelial lesion and invasive stratified mucin-producing carcinoma. ( 29144557 )
2017
48
MAML2 Rearrangements in Variant Forms of Mucoepidermoid Carcinoma: Ancillary Diagnostic Testing for the Ciliated and Warthin-like Variants. ( 28877061 )
2017
49
Sclerosing Mucoepidermoid Carcinoma in the Parotid Gland With CRTC1-MAML2 Fusion: A Case Report. ( 29169286 )
2017
50
Expression of Vascular Endothelial-Cadherin in Mucoepidermoid Carcinoma: Role in Cancer Development. ( 29387612 )
2017

Variations for Mucoepidermoid Carcinoma

Cosmic variations for Mucoepidermoid Carcinoma:

9
(show top 50) (show all 125)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6915468 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 16
2 COSM44850 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 15
3 COSM46283 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 15
4 COSM43680 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 15
5 COSM44119 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161A 17:7675129-7675129 15
6 COSM43797 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.550G>C p.D184H 17:7675062-7675062 15
7 COSM46282 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 15
8 COSM44853 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 15
9 COSM1389051 SMAD4 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.993G>A p.M331I 18:51065460-51065460 15
10 COSM5995773 SDHA salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.724G>A p.G242R 5:228287-228287 15
11 COSM5069 PTEN salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.760A>G p.K254E 10:87957978-87957978 15
12 COSM546 KRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.175G>A p.A59T 12:25227349-25227349 15
13 COSM483 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 15
14 COSM491 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.39T>A p.G13G 11:534284-534284 15
15 COSM489 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.38G>T p.G13V 11:534285-534285 15
16 COSM484 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.35G>A p.G12D 11:534288-534288 15
17 COSM3596039 BAP1 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.376-1G>A p.? 3:52407461-52407461 15
18 COSM120918 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.38G>T p.G13V 11:534285-534285 15
19 COSM10648 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 12
20 COSM69404 TP53 salivary gland,minor,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 12
21 COSM11552 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 12
22 COSM6935085 TENT5C salivary gland,minor,carcinoma,NS c.833T>A p.F278Y 1:117623701-117623701 12
23 COSM4728291 SMARCA4 salivary gland,minor,carcinoma,NS c.2372C>T p.A791V 19:11013046-11013046 12
24 COSM6915408 SF3B1 salivary gland,minor,carcinoma,NS c.3254C>T p.A1085V 2:197397997-197397997 12
25 COSM6910358 SETD2 salivary gland,minor,carcinoma,NS c.4870C>T p.Q1624* 3:47057405-47057405 12
26 COSM41699 RUNX1 salivary gland,minor,carcinoma,NS c.958C>T p.R320* 21:34799310-34799310 12
27 COSM6928612 RPTOR salivary gland,minor,carcinoma,NS c.734C>T p.A245V 17:80754089-80754089 12
28 COSM6910364 RARA salivary gland,minor,carcinoma,NS c.691C>G p.L231V 17:40352391-40352391 12
29 COSM13023 PTPN11 salivary gland,minor,carcinoma,NS c.1505C>T p.S502L 12:112489081-112489081 12
30 COSM6935088 PIK3CG salivary gland,minor,carcinoma,NS c.2951C>A p.P984Q 7:106886213-106886213 12
31 COSM757 PIK3CA salivary gland,minor,carcinoma,NS c.1258T>C p.C420R 3:179210192-179210192 12
32 COSM1420934 PIK3CA salivary gland,minor,carcinoma,NS c.3012G>A p.M1004I 3:179234169-179234169 12
33 COSM763 PIK3CA salivary gland,minor,carcinoma,NS c.1633G>A p.E545K 3:179218303-179218303 12
34 COSM6913851 PBRM1 salivary gland,minor,carcinoma,NS c.2284G>C p.D762H 3:52609596-52609596 12
35 COSM6909937 NOTCH1 salivary gland,minor,carcinoma,NS c.973A>G p.N325D 9:136518717-136518717 12
36 COSM6916910 NOTCH1 salivary gland,minor,carcinoma,NS c.403+1G>C p.? 9:136523716-136523716 12
37 COSM13044 NOTCH1 salivary gland,minor,carcinoma,NS c.5101G>C p.A1701P 9:136503248-136503248 12
38 COSM3929943 NOTCH1 salivary gland,minor,carcinoma,NS c.1367G>A p.C456Y 9:136517826-136517826 12
39 COSM13081 NOTCH1 salivary gland,minor,carcinoma,NS c.7400C>A p.S2467* 9:136496339-136496339 12
40 COSM6842736 NF1 salivary gland,minor,carcinoma,NS c.3449C>G p.S1150* 17:31232834-31232834 12
41 COSM6910361 MAX salivary gland,minor,carcinoma,NS c.295+1G>A p.? 14:65077912-65077912 12
42 COSM6927303 MAP2K4 salivary gland,minor,carcinoma,NS c.551C>G p.S184W 17:12107827-12107827 12
43 COSM4042348 KMT2D salivary gland,minor,carcinoma,NS c.12640C>T p.R4214* 12:49031255-49031255 12
44 COSM51381 KIT salivary gland,face,carcinoma,NS c.2386A>G p.R796G 4:54733094-54733094 12
45 COSM6925975 HGF salivary gland,minor,carcinoma,NS c.1444+1G>A p.? 7:81711480-81711480 12
46 COSM6910360 FGFR3 salivary gland,minor,carcinoma,NS c.1682G>C p.G561A 4:1805786-1805786 12
47 COSM6916439 EZH2 salivary gland,minor,carcinoma,NS c.938G>A p.R313Q 7:148819657-148819657 12
48 COSM6935087 ETV1 salivary gland,minor,carcinoma,NS c.971G>T p.R324L 7:13906569-13906569 12
49 COSM1242240 ERBB3 salivary gland,minor,carcinoma,NS c.695C>T p.A232V 12:56087876-56087876 12
50 COSM6913854 EP300 salivary gland,minor,carcinoma,NS c.3110C>T p.S1037L 22:41152318-41152318 12

Expression for Mucoepidermoid Carcinoma

Search GEO for disease gene expression data for Mucoepidermoid Carcinoma.

Pathways for Mucoepidermoid Carcinoma

GO Terms for Mucoepidermoid Carcinoma

Cellular components related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 AREG CALCA CHGA EGFR MUC1 MUC4
2 keratin filament GO:0045095 9.43 KRT13 KRT14 KRT7
3 Golgi lumen GO:0005796 8.92 MUC1 MUC2 MUC4 MUC5AC
4 nucleus GO:0005634 10 AREG CALCA CRTC1 CRTC3 EGFR ERBB2

Biological processes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.63 AREG EGFR PCNA
2 protein homotetramerization GO:0051289 9.5 CRTC1 CRTC3 TP63
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.49 MUC1 TP63
4 positive regulation of CREB transcription factor activity GO:0032793 9.48 CRTC1 CRTC3
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.46 MUC1 MUC2 MUC4 MUC5AC
6 negative regulation of ERBB signaling pathway GO:1901185 9.43 EGFR ERBB2
7 positive regulation of DNA replication GO:0045740 9.43 AREG EGFR PCNA
8 cell proliferation GO:0008283 9.43 AREG EGFR ERBB2 MKI67 PCNA TP63
9 positive regulation of cAMP metabolic process GO:0030816 9.4 CALCA CHGA
10 maintenance of gastrointestinal epithelium GO:0030277 9.37 MUC2 MUC4
11 O-glycan processing GO:0016266 8.92 MUC1 MUC2 MUC4 MUC5AC

Molecular functions related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR ERBB2
2 cAMP response element binding protein binding GO:0008140 8.62 CRTC1 CRTC3

Sources for Mucoepidermoid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....